Akkermansia Muciniphila Buy

"As a registered dietitian, I often get asked how to improve gut health. Akkermansia muciniphila is a keystone strain that has been shown to help improve overall gut health and strengthen the gut-lining. This live probiotic strain can only be found in Pendulum products!"

akkermansia muciniphila buy

Did you imagine one little gut bacteria species had so much potential for your health? Since Akkermansia muciniphila is relatively new to science, supplement options are almost nonexistent and not very well tested. Instead of supplements, we recommend using healthy fats to encourage an environment where intestinal mucus is healthy and readily available for this unique probiotic. Our Balance Oil gives your body all the essential fatty acid building blocks it needs for a strong intestinal lining. It supports brain health, gut health, and liver function and can help your Akkermansia muciniphila grow and thrive.Nourish Your Akkermansia with Balance Oil

P.D.C. conceived the project. J.-P.T., M.P.H., A.L., D.M., A.E., C. Depommier, C. Druart, H.P., M.V.H., W.M.d.V. and P.D.C. designed the clinical study. P.D.C. supervised the clinical part of the study and W.M.d.V. contributed to the microbial culturing of A. muciniphila. P.D.C., A.E., C. Depommier, C. Druart, M.d.B., J.-P.T., A.L., D.M. and M.P.H. performed the clinical part of the study. N.M.D. contributed to interpretation of the results. S.V.-S., G.F. and J.R. performed the fecal microbiome sequencing and analysis. P.D.C., A.E. and C. Depommier performed the experiments and interpreted all the results. P.D.C., A.E. and C. Depommier generated the figures and tables. P.D.C. and C. Depommier wrote the manuscript. All authors discussed the results and approved the manuscript.

A.E., C. Druart, H.P., P.D.C. and W.M.d.V. are inventors of patent applications (nos. PCT/EP2013/073972, PCT/EP2016/071327 and PCT/EP2016/060033 filed with the European Patent Office, Australia, Brazil, Canada, China, the Eurasian Patent Organization, Israel, India, Hong Kong, Japan, South Korea, Mexico, New Zealand and the United States) dealing with the use of A. muciniphila and its components in the context of obesity and related disorders. P.D.C. and W.M.d.V. are cofounders of A-Mansia Biotech S.A.

For instance, a study that Medical News Today reported on in 2016 found that A. muciniphila, a bacterium that lives in the mucus layer of the gut, can prevent obesity and obesity-related type 2 diabetes in mice when administered in pasteurized form.

Now, in a new study in humans, Prof. Cani and his team confirm that giving A. muciniphila as a nutritional supplement to people with metabolic syndrome improves their cardiometabolic health, in the same way that it has in mice.

Grajeda-Iglesias C, Durand S, Daillère R, Iribarren K, Lemaitre F, Derosa L, Aprahamian F, Bossut N, Nirmalathasan N, Madeo F, Zitvogel L, Kroemer G, . Oral administration of Akkermansia muciniphila elevates systemic antiaging and anticancer metabolites. Aging (Albany NY). 2021 Mar 2; 13:6375-6405.

The presence of Akkermansia muciniphila (Akk) in the human gut is associated with good health, leanness and fitness. Mouse experimentation has demonstrated positive effects for Akk, which counteracts aging, mediates antiobesity and antidiabetic effects, dampens inflammation and improves anticancer immunosurveillance. Clinical trials have confirmed antidiabetic effects for Akk. Here, we investigated the time-dependent effects of oral administration of Akk (which was live or pasteurized) and other bacteria to mice on the metabolome of the ileum, colon, liver and blood plasma. Metabolomics was performed by a combination of chromatographic and mass spectrometric methods, yielding a total of 1.637.227 measurements. Akk had major effects on metabolism, causing an increase in spermidine and other polyamines in the gut and in the liver. Pasteurized Akk (Akk-past) was more efficient than live Akk in elevating the intestinal concentrations of polyamines, short-chain fatty acids, 2-hydroxybutyrate, as well multiple bile acids, which also increased in the circulation. All these metabolites have previously been associated with human health, providing a biochemical basis for the beneficial effects of Akk.

The Reducing Enteropathy, Undernutrition, and Contamination in the Environment (REDUCE) study focuses on identifying pathways of exposure to fecal pathogens that are significant contributors to diarrheal diseases for young children in the DRC, and on developing and evaluating scalable interventions to reduce fecal contamination from these pathways. Our primary objective in conducting this prospective cohort study was to determine whether the presence and quantity of enteric microorganisms, including L. salivarius and A. muciniphila, in feces was significantly associated with growth in young children in rural DRC. We hypothesized that the enteric pathogens Giardia, Shigella, Cryptosporidium spp., and Campylobacter jejuni would impair child growth by increasing intestinal inflammation and reducing nutrient absorption. Conversely, we hypothesized that L. salivarius and A. muciniphila would improve child growth by reducing intestinal inflammation and facilitating nutrient absorption.

In this prospective cohort study conducted in rural eastern DRC, we found that A. muciniphila was associated with improved linear growth in young children, Cryptosporidium was associated with impaired growth, and two thirds of children had a high prevalence (>3) of enteric pathogens in their feces. Children with Cryptosporidium in their feces, as measured by WHLZ, grew more poorly as the abundance of the pathogen increased. In contrast, A. muciniphila in feces was associated with improved linear growth. This promising finding suggests that A. muciniphila may have the potential to serve a probiotic role to help improve growth in young children; however, experimental studies must first be conducted to prove this potential benefit. Children are most susceptible to linear growth faltering during the first 2 years of life (31), and effective interventions are urgently needed to improve child health during this critical window of development.

Our finding that A. muciniphila was associated with improvements in linear growth is consistent with a recent cross-sectional study among children in GEMS, which found that children who had A. muciniphila in their feces had higher HAZ than did children who did not (Almeida et al., unpub. data). Previous studies in adult populations have found A. muciniphila more abundant in healthy persons compared with those with inflammatory bowel disease (32). A. muciniphila resides in the intestinal mucin which may serve as its carbon source (33). We hypothesize that A. muciniphila impacts the gut mucosal barrier through reducing intestinal inflammation. Our results, however, do not imply causality, and our study is not a substitute for a randomized clinical trial. Low A. muciniphila presence may be a marker of pathogenic processes, such as increased intestinal inflammation, contributing to poor child growth, but the microbe itself may not be directly influencing child growth. Mechanistic studies are needed to further investigate our observed association between A. muciniphila and child growth.

Findings from human and animal studies suggest that A. muciniphila is a highly promising probiotic (34). Oral A. muciniphila supplementation improved clinical responses to immune checkpoint inhibitors targeting the PD-1/PD-L1 (programmed death-1/programmed death ligand-1) axis in animal studies (35), and A. muciniphila reduced biomarkers of liver dysfunction and inflammation among persons who were overweight or obese (36); however, no studies have investigated its effect on child growth or diarrhea. Rhubarb extract has been shown to promote A. muciniphila abundance (34) and might therefore serve as a potential natural source of increased A. muciniphila. Future mechanistic studies are needed to determine if A. muciniphila is associated with decreased enteric inflammation and systemic inflammation. Experimental studies are needed to investigate our observed association between A. muciniphila and child growth in other global settings to determine whether this commensal microbe can be used as a potential therapeutic agent to improve child growth.

In our community-based prospective cohort study, young children had a high burden of enteric pathogens in eastern DRC. We found Cryptosporidium in feces was associated with growth faltering, further evidence to support the role of enteric pathogens on child growth in a sub-Saharan Africa setting and highlighting the need for interventions to reduce pediatric exposure to fecal pathogens. Our results also show that A. muciniphila was associated with improved linear growth in young children, illustrating the potential of this enteric microbe to serve as a therapeutic intervention for this high-risk population and suggesting pathways for future research globally.

There have been many reports on the roles of intestinal flora and intestinal environment in health promotion and disease prevention. Beneficial bacteria such as Bifidobacterium and lactic acid-producing bacteria have been shown to improve the intestinal environment, and yield a good effect on metabolism, immunity and nerve response. In this review, in addition to these beneficial bacteria, we introduced Akkermansia muciniphila as a next-generation beneficial microbe. Several reports indicate that Akkermansia muciniphila affects glucose metabolism, lipid metabolism, and intestinal immunity, and that certain food ingredients such as polyphenols may increase the abundance of Akkermansia muciniphila in the gut.

Increasing populations of these protective keystone bacteria like Akkermansia muciniphila, Faecalibacterium prausnitzii, and Bifidobacterium species is an integral part of reinforcing a healthy gut microbiome.*

Obesity and type 2 diabetes are characterized by altered gut microbiota, inflammation, and gut barrier disruption. Microbial composition and the mechanisms of interaction with the host that affect gut barrier function during obesity and type 2 diabetes have not been elucidated. We recently isolated Akkermansia muciniphila, which is a mucin-degrading bacterium that resides in the mucus layer. The presence of this bacterium inversely correlates with body weight in rodents and humans. However, the precise physiological roles played by this bacterium during obesity and metabolic disorders are unknown. This study demonstrated that the abundance of A. muciniphila decreased in obese and type 2 diabetic mice. We also observed that prebiotic feeding normalized A. muciniphila abundance, which correlated with an improved metabolic profile. In addition, we demonstrated that A. muciniphila treatment reversed high-fat diet-induced metabolic disorders, including fat-mass gain, metabolic endotoxemia, adipose tissue inflammation, and insulin resistance. A. muciniphila administration increased the intestinal levels of endocannabinoids that control inflammation, the gut barrier, and gut peptide secretion. Finally, we demonstrated that all these effects required viable A. muciniphila because treatment with heat-killed cells did not improve the metabolic profile or the mucus layer thickness. In summary, this study provides substantial insight into the intricate mechanisms of bacterial (i.e., A. muciniphila) regulation of the cross-talk between the host and gut microbiota. These results also provide a rationale for the development of a treatment that uses this human mucus colonizer for the prevention or treatment of obesity and its associated metabolic disorders. 041b061a72